Grail has announced a multi-faceted partnership with Ochsner Health to offer the Galleri multi-cancer early detection (MCED) blood test in Louisiana, US.
Galleri can detect more than 50 types of cancer from a blood sample and enables earlier treatment.
It predicts the cancer signal origin, or the location of the disease in the body, with high accuracy, when a signal is detected. This helps to guide the next steps of a diagnosis.
The company stated that the test will be offered by prescription from licensed health care providers to eligible patients with an elevated risk of cancer due to their age, such as people aged 50 and above.
As part of the collaboration, Ochsner Health will offer the Galleri test to eligible patients in Louisiana through a collaboration between its Ochsner Cancer Institute and Precision Medicine programme.
Grail noted that the test should be used in addition to recommended cancer screening tests, such as colonoscopy, mammography, prostate-specific antigen (PSA) tests or cervical cancer screening.
The collaboration also includes the launch of a three-year MCED Health Equity Demonstration Programme, which aims to improve cancer detection rates among underserved people in Louisiana.
The initiative also aims to develop best practices to deploy innovative technologies in community settings.
Grail CEO Bob Ragusa said: “We are excited to join forces with Ochsner in this effort, as both organisations have a shared vision for increasing early cancer detection and a focus on improving outcomes in underserved communities.
“By jointly launching a real-world evidence programme to evaluate the impact of Galleri, we can not only help make a difference for underserved populations but also collect critical insights that will help us develop a best-practice roadmap for integrating MCED testing that can be scaled and brought to other communities, helping to bridge the health equity gap in cancer detection.”
Additionally, Ochsner will start enrolling subjects aged 50 years and above who are not being assessed or treated for cancer in the ongoing PATHFINDER 2 study, which will evaluate the safety and performance of the Galleri test.
The multi-centre, prospective interventional test aims to enrol 20,000 subjects in North America.